Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Rajbir Singh, Ramakrishna Rachumallu, Manisha Bhateria, Jagadeesh Panduri & Rabi Sankar Bhatta. (2015) In vitro effects of standardized extract of Bacopa monniera and its five individual active constituents on human P-glycoprotein activity. Xenobiotica 45:8, pages 741-749.
Read now
Read now
Fang Zhou, Jingwei Zhang, Peng Li, Fang Niu, Xiaolan Wu, Guangji Wang & Michael S. Roberts. (2011) Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metabolism Reviews 43:3, pages 335-345.
Read now
Read now
D. M. Ross & T. P. Hughes. (2008) Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology 40:3, pages 231-246.
Read now
Read now
Jianling Wang, Laszlo Urban & Dejan Bojanic. (2007) Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 641-665.
Read now
Read now
Soumyajit Majumdar & Ashim K Mitra. (2006) Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opinion on Drug Delivery 3:4, pages 511-527.
Read now
Read now
Graham Lappin, Malcolm Rowland & R Colin Garner. (2006) The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opinion on Drug Metabolism & Toxicology 2:3, pages 419-427.
Read now
Read now
Articles from other publishers (47)
Muhammad Raza Shah, Muhammad Imran & Shafi Ullah. 2019. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy
1
21
.
Guoyu Pan. 2019. Drug Transporters in Drug Disposition, Effects and Toxicity. Drug Transporters in Drug Disposition, Effects and Toxicity
293
340
.
G. Riu, L. Gaba, I. Victoria, G. Molas, F. do Pazo, B. Gómez, N. Creus & L. Vidal. (2018) Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. European Journal of Cancer Care 27:1, pages e12447.
Crossref
Crossref
E. Martin, L. Pourtau, M. Di Palma & S. Delaloge. (2017) New oral targeted therapies for metastatic breast cancer disrupt the traditional patients’ management-A healthcare providers’ view. European Journal of Cancer Care 26:6, pages e12624.
Crossref
Crossref
Pauline Bosco-Lévy, Paul de Boissieu, Amandine Gouverneur, Pernelle Noize, Mathieu Molimard, Annie Fourrier-Réglat & Julien Bezin. (2017) National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiology and Drug Safety 26:10, pages 1233-1241.
Crossref
Crossref
E. Sawicki, J.H.M. Schellens, J.H. Beijnen & B. Nuijen. (2016) Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treatment Reviews 50, pages 247-263.
Crossref
Crossref
Emilia Sawicki, Michel J. Hillebrand, Hilde Rosing, Jan H.M. Schellens, Bastiaan Nuijen & Jos H. Beijnen. (2016) Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar. Journal of Pharmaceutical Analysis 6:4, pages 268-275.
Crossref
Crossref
Tyler B. Hughes, Grover P. Miller & S. Joshua Swamidass. (2015) Site of Reactivity Models Predict Molecular Reactivity of Diverse Chemicals with Glutathione. Chemical Research in Toxicology 28:4, pages 797-809.
Crossref
Crossref
Sudhakar Garad & Akash Jain. 2015. Discovering and Developing Molecules with Optimal Drug-Like Properties. Discovering and Developing Molecules with Optimal Drug-Like Properties
3
47
.
Christine M Bestvina, Leah L Zullig & S Yousuf Zafar. (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncology 10:14, pages 2189-2199.
Crossref
Crossref
Patricia CallejaSocorro EspuelasLeticia Corrales, Ruben Pio & Juan M Irache. (2014) Pharmacokinetics and antitumor efficacy of paclitaxel–cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration. Nanomedicine 9:14, pages 2109-2121.
Crossref
Crossref
Alejandro Sosnik. (2013) Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review. Advanced Drug Delivery Reviews 65:13-14, pages 1828-1851.
Crossref
Crossref
Maged Mansour & Cynthia Mourad. (2013) Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. Cancer Chemotherapy and Pharmacology 72:2, pages 429-435.
Crossref
Crossref
Shengnan Tang, Dawei Gao, Tingting Zhao, Jing Zhou & Xiaoning Zhao. (2013) An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes. Nanotechnology 24:23, pages 235102.
Crossref
Crossref
Frederik E. Stuurman, Bastiaan Nuijen, Jos H. Beijnen & Jan H. M. Schellens. (2013) Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement. Clinical Pharmacokinetics 52:6, pages 399-414.
Crossref
Crossref
Ziyad Binkhathlan & Aws Alshamsan. (2012) Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments. Therapeutic Delivery 3:9, pages 1117-1130.
Crossref
Crossref
Ziyad Binkhathlan, Anooshirvan Shayeganpour, Dion R. Brocks & Afsaneh Lavasanifar. (2012) Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. European Journal of Pharmaceutics and Biopharmaceutics 81:1, pages 142-148.
Crossref
Crossref
Antonio Ruggiero, Maria G. Cefalo, Paola Coccia, Stefano Mastrangelo, Palma Maurizi & Riccardo Riccardi. (2011) The role of diet on the clinical pharmacology of oral antineoplastic agents. European Journal of Clinical Pharmacology 68:2, pages 115-122.
Crossref
Crossref
Patricia Calleja, Judit Huarte, Maite Agüeros, Luisa Ruiz-Gatón, Socorro Espuelas & Juan M Irache. (2012) Molecular buckets: cyclodextrins for oral cancer therapy. Therapeutic Delivery 3:1, pages 43-57.
Crossref
Crossref
Han Byul Kang, Hong-Kun Rim, Jin Yeong Park, Heung Woo Choi, Doo Li Choi, Ji-Hyung Seo, Kyung-Sook Chung, Geun Huh, Jungahn Kim, Dong Joon Choo, Kyung-Tae Lee & Jae Yeol Lee. (2012) In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor. Bioorganic & Medicinal Chemistry Letters 22:2, pages 1198-1201.
Crossref
Crossref
Yoon Gyoon Kim & Keon Wook Kang. (2011) Application of drug metabolism and pharmacokinetics for new drug development. Archives of Pharmacal Research 34:11, pages 1769-1771.
Crossref
Crossref
Maria L. H. Vlaming, Anita van Esch, Evita van de Steeg, Zeliha Pala, Els Wagenaar, Olaf van Tellingen & Alfred H. Schinkel. (2011) Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate. Drug Metabolism and Disposition 39:8, pages 1338-1344.
Crossref
Crossref
I. Leitner, J. Nemeth, T. Feurstein, A. Abrahim, P. Matzneller, H. Lagler, T. Erker, O. Langer & M. Zeitlinger. (2011) The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. Journal of Antimicrobial Chemotherapy 66:4, pages 834-839.
Crossref
Crossref
Socorro Espuelas, Maite Agüeros, Irene Esparza & Juan M. Irache. 2011. Intracellular Delivery. Intracellular Delivery
487
509
.
Giuseppe Luigi Banna, Elena Collovà, Vittorio Gebbia, Helga Lipari, Pietro Giuffrida, Sebastiano Cavallaro, Rosaria Condorelli, Calogero Buscarino, Paolo Tralongo & Francesco Ferraù. (2010) Anticancer oral therapy: Emerging related issues. Cancer Treatment Reviews 36:8, pages 595-605.
Crossref
Crossref
Catherine C. Simmons. (2010) Medicamentos de quimioterapia por vía oral: adminístrelos con cuidado. Nursing (Ed. española) 28:10, pages 14-17.
Crossref
Crossref
Catherine C. Simmons. (2010) Oral chemotherapeutic drugs. Nursing 40:7, pages 44-47.
Crossref
Crossref
Huan Qiu, Marianne Mathäs, Sebastian Nestler, Christopher Bengel, Dieudonne Nem, Ute Gödtel–Armbrust, Thomas Lang, Stefan Taudien, Oliver Burk & Leszek Wojnowski. (2010) The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenetics and Genomics 20:1, pages 167-178.
Crossref
Crossref
Praveen M. Bahadduri, James E. Polli, Peter W. Swaan & Sean Ekins. 2010. Membrane Transporters in Drug Discovery and Development. Membrane Transporters in Drug Discovery and Development
65
103
.
Sudhakar Garad, Jianling Wang, Yatindra Joshi & Riccardo Panicucci. 2010. Pharmaceutical Suspensions. Pharmaceutical Suspensions
127
176
.
Wayne L. FurmanFariba NavidNajat C. DawM. Beth McCarvilleLisa M. McGregorSheri L. SpuntCarlos Rodriguez-GalindoJohn C. PanettaKristine R. CrewsJianrong WuAmar J. GajjarPeter J. HoughtonVictor M. SantanaClinton F. Stewart. (2009) Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology 27:27, pages 4599-4604.
Crossref
Crossref
E.H. Tan, J. Rolski, T. Grodzki, C.P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y.H. Tsai & R. Abratt. (2009) Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology 20:7, pages 1249-1256.
Crossref
Crossref
Maria L.H. Vlaming, Zeliha Pala, Anita van Esch, Els Wagenaar, Dirk R. de Waart, Koen van de Wetering, Cornelia M.M. van der Kruijssen, Ronald P.J. Oude Elferink, Olaf van Tellingen & Alfred H. Schinkel. (2009)
Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate
In vivo
. Clinical Cancer Research 15:9, pages 3084-3093.
Crossref
Crossref
Taher Nassar, Alona Rom, Abraham Nyska & Simon Benita. (2009) Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. Journal of Controlled Release 133:1, pages 77-84.
Crossref
Crossref
Dirk M. Hermann. (2008) Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood—brain barrier. Therapeutic Advances in Neurological Disorders 1:3, pages 167-179.
Crossref
Crossref
N. Lloberas, J. Torras, G. Alperovich, J. M. Cruzado, P. Gimenez-Bonafe, I. Herrero-Fresneda, M.{m. d.}l. Franquesa, I. Rama & J. M. Grinyo. (2008) Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrology Dialysis Transplantation 23:10, pages 3111-3119.
Crossref
Crossref
Jason M. Gow, Laura M. Hodges, Leslie W. Chinn & Deanna L. Kroetz. (2008)
Substrate-Dependent Effects of Human
ABCB1
Coding Polymorphisms
. Journal of Pharmacology and Experimental Therapeutics 325:2, pages 435-442.
Crossref
Crossref
M. Findlay, G. von Minckwitz & A. Wardley. (2008) Effective oral chemotherapy for breast cancer: pillars of strength. Annals of Oncology 19:2, pages 212-222.
Crossref
Crossref
Nielka P. van Erp, Hans Gelderblom, Mats O. Karlsson, Jing Li, Ming Zhao, Jan Ouwerkerk, Johan W. Nortier, Henk-Jan Guchelaar, Sharyn D. Baker & Alex Sparreboom. (2007) Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Clinical Cancer Research 13:24, pages 7394-7400.
Crossref
Crossref
Tripta Bansal, Manoj Singh, Gautam Mishra, Sushama Talegaonkar, Roop K. Khar, Manu Jaggi & Rama Mukherjee. (2007) Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: Utility in Caco-2 intestinal absorption studies. Journal of Chromatography B 859:2, pages 261-266.
Crossref
Crossref
Jianling Wang, Laszlo Urban & Dejan Bojanic. (2007)
Maximising use of
in vitro
ADMET tools to predict
in vivo
bioavailability and safety
. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 641-665.
Crossref
Crossref
Ritu Aneja, Neerupma Dhiman, Jyoti Idnani, Anshumali Awasthi, Sudershan K. Arora, Ramesh Chandra & Harish C. Joshi. (2007) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemotherapy and Pharmacology 60:6, pages 831-839.
Crossref
Crossref
Robert W. Robey, Orsolya Polgar, John Deeken, Kin Wah To & Susan E. Bates. (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews 26:1, pages 39-57.
Crossref
Crossref
Philippe Labrie, Shawn. P. Maddaford, Jacques Lacroix, Concettina Catalano, David K.H. Lee, Suman Rakhit & René C. Gaudreault. (2006) In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450. Bioorganic & Medicinal Chemistry 14:23, pages 7972-7987.
Crossref
Crossref
Walter Brand, Maaike E. Schutte, Gary Williamson, Jelmer J. van Zanden, Nicole H.P. Cnubben, John P. Groten, Peter J. van Bladeren & Ivonne M.C.M. Rietjens. (2006) Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomedicine & Pharmacotherapy 60:9, pages 508-519.
Crossref
Crossref
Maurie Markman. (2006) The “new” era of oral antineoplastic drug therapy: Revisiting “old” concerns. Current Oncology Reports 8:5, pages 317-318.
Crossref
Crossref
Manthena VS Varma, Omathanu P Perumal & Ramesh Panchagnula. (2006) Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Current Opinion in Chemical Biology 10:4, pages 367-373.
Crossref
Crossref